Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Mega-Mergers Were Just The Highlights Of A Year Of Major Deals

Executive Summary

BMS/Celgene and AbbVie/Allergan were the biggest biopharma deals by dollar value in 2019, and the third and seventh largest ever. The year saw 23 deals valued at $1bn or more, including 20 M&A agreements.

You may also be interested in...



AbbVie/Allergan Merger Edges Closer To FTC Clearance

AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.

Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer

With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.

Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141477

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel